Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic competitive advantages within the Indian CRO industry and his personal aspiration to reach the USD 200 million goal by 2021.
Could you tell us about GVK in terms of the structure of the organization and how the entire conglomerate helps GVK BIO strengthen its position?
"We are discovering the intellectual property for our customers, that makes us very strategic and important for them."
